<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02462161</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00026106</org_study_id>
    <secondary_id>5P50AG005136-30</secondary_id>
    <nct_id>NCT02462161</nct_id>
  </id_info>
  <brief_title>Study of Nasal Insulin to Fight Forgetfulness - Short-Acting Insulin Aspart</brief_title>
  <acronym>SNIFF-Quick</acronym>
  <official_title>Study of Nasal Insulin to Fight Forgetfulness - Short-Acting Insulin Aspart</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>General Electric</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot clinical trial will examine the effects of intranasal insulin aspart on cognition,
      daily function, blood and cerebral spinal fluid markers of Alzheimer's disease, and amyloid
      deposition in the brain. Participants will be randomly assigned to receive insulin aspart or
      placebo during a 12-week treatment period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A growing body of evidence suggests that insulin plays a role in normal memory processes and
      that insulin abnormalities may contribute to cognitive and brain changes associated with
      Alzheimer's disease (AD). Interestingly, insulin administered to the nasal cavity is
      transported within a few minutes into the brain, but does not affect blood sugar or insulin
      levels.

      This trial will consist of a randomized double-blind, placebo-controlled parallel group trial
      in which 30 participants with AD or mild cognitive impairment (MCI) receive twice daily
      intranasal administrations of insulin aspart (20 IU) or placebo (saline), two times per day
      for 12 weeks. All participants will appoint a &quot;support person&quot; to answer a collateral
      questionnaire and supervise the administration of the study drug. All participants and study
      partners will undergo the intensive, structured training program in the self-management of
      intranasal insulin administration. Cognitive testing and blood collection will occur at
      baseline, after 6 weeks of treatment, and at the end of the 12 week treatment period.
      Participants will also receive a lumbar puncture to measure AD biomarkers in the subject's
      cerebral spinal fluid.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 20, 2015</start_date>
  <completion_date type="Actual">April 16, 2019</completion_date>
  <primary_completion_date type="Actual">April 16, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in cognition</measure>
    <time_frame>6 weeks and 12 weeks</time_frame>
    <description>Alzheimer's Disease Assessment Scale-Cognitive Subscale(ADAS-Cog)/mild cognitive impairment (MCI) scores and memory composite (summed Z scores from delayed story and list recall)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cerebral spinal fluid (CSF) and blood amyloid-beta, tau protein, and inflammatory markers</measure>
    <time_frame>Blood - every 6 weeks for 12 weeks; cerebral spinal fluid (CSF) - baseline and week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRI measure of cortical thickness in Alzheimer's disease (AD) -vulnerable regions</measure>
    <time_frame>Baseline and week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Alzheimer's Disease</condition>
  <condition>Mild Cognitive Impairment</condition>
  <arm_group>
    <arm_group_label>Insulin Aspart</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fifteen randomly assigned participants with Alzheimer's disease or mild cognitive impairment will receive twice daily intranasal administrations of insulin aspart (20 IU) for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Fifteen randomly assigned participants with Alzheimer's disease or mild cognitive impairment will receive twice daily intranasal administrations of placebo (saline) for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin aspart</intervention_name>
    <description>Participants will administer 20 IU insulin aspart two times per day with an intranasal delivery device.</description>
    <arm_group_label>Insulin Aspart</arm_group_label>
    <other_name>NovoLog Fast-Acting Insulin Aspart</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will administer placebo two times per day with an intranasal delivery device.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Previous or subsequent diagnosis of Alzheimer's disease or mild cognitive impairment

          -  Ability to communicate in English

        Exclusion Criteria:

          -  Preexisting diabetes

          -  Clinically significant elevations in liver function test

          -  Clinically significant elevations in lipid profile

          -  Prior lumbar lumbar surgeries or other medical conditions that render lumbar punctures
             unsafe

          -  Hemoglobin &lt;8 g/dl

          -  Significant neurologic disease that might affect cognition, other than Alzheimer's
             disease, including stroke, Parkinson's disease, multiple sclerosis, or recent severe
             head injury (within the last year) with loss of consciousness &gt;30 minutes or with
             permanent neurologic sequelae

          -  Significant medical illness or organ failure, such as uncontrolled hypertension or
             cardiovascular disease, chronic obstructive pulmonary disease, liver disease, or
             kidney disease

          -  Current use of antipsychotic, anticonvulsant, anxiolytic, anticoagulant or sedative
             medications

          -  Current or previous use of glucose-lowering agents or insulin;

          -  Chronic use (â‰¥ 3 times per week) of nasal sprays of any type for any indication

          -  Premenopausal status (defined as having had a period within the last year).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suzanne Craft, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wake Forest Baptist Hospital</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>June 1, 2015</study_first_submitted>
  <study_first_submitted_qc>June 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2015</study_first_posted>
  <last_update_submitted>May 8, 2020</last_update_submitted>
  <last_update_submitted_qc>May 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
    <mesh_term>Insulin, Long-Acting</mesh_term>
    <mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 30, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/61/NCT02462161/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

